Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Leon D. Ortiz"'
Publikováno v:
Frontiers in Endocrinology, Vol 9 (2018)
Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improve
Externí odkaz:
https://doaj.org/article/e9f47dda7b36437398af5c5f36dba6c4
Autor:
Luis V. Syro, Bernd W. Scheithauer, Kalman Kovacs, Rodrigo A. Toledo, Francisco J. Londoño, Leon D. Ortiz, Fabio Rotondo, Eva Horvath, Humberto Uribe
Publikováno v:
Clinics, Vol 67, Pp 43-48 (2012)
We briefly review the characteristics of pituitary tumors associated with multiple endocrine neoplasia type 1. Multiple endocrine neoplasia type 1 is an autosomal-dominant disorder most commonly characterized by tumors of the pituitary, parathyroid,
Externí odkaz:
https://doaj.org/article/2d1a9c2642fb4dfa85fbb8c93a5f665c
Autor:
Leon D. Ortiz, Luis V. Syro, Bernd W. Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E. Fadul, Eva Horvath, Kalman Kovacs
Publikováno v:
Clinics, Vol 67, Pp 119-123 (2012)
Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6-methylguanine-DNA methyltransferase, a DNA repa
Externí odkaz:
https://doaj.org/article/59aea8a3095d41f9bc71f63cd9fe6da3
Publikováno v:
Pituitary. 20:84-92
Histologic, immunohistochemical and electron microscopic studies have provided conclusive evidence that a marked diversity exists between tumors which secrete growth hormone (GH) in excess. GH cell hyperplasia can also be associated with acromegaly i
Publikováno v:
Frontiers in Endocrinology, Vol 9 (2018)
Frontiers in Endocrinology
Frontiers in Endocrinology
Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improve
Publikováno v:
Endocrine-related cancer. 25(8)
Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2
Autor:
Ann McCormack, Olaf M Dekkers, Stephan Petersenn, Vera Popovic, Jacqueline Trouillas, Gerald Raverot, Pia Burman, Alicia Hubalewska-Dydejezky, Guillaume Assie, Leon Bach, Marie Batisse-Lignier, Katarina Berinder, Ismene Bilbao, Fabrice Bonnet, Damien Bresson, Oscar Bruno, Mariana Campdera, Philippe Caron, Frederic Castinetti, Filippo Ceccato, Olivier Chabre, Philippe Chanson, Emanuel Christ, Lucie Cloix, Christine Cortet, Lise Criniere, Guillem Cuatrecasas, Miguel Debono, Brigitte Delemer, Rachel Desailloud, Timo Deutschbein, Tina Dusek, Britt Eden Engström, Marco Faustini-Fustini, Schillo Franck, Cyril Garcia, Yona Greenman, Susana Mallea Gil, Giovanna Mantovani, Mark Gurnell, Anthony Heaney, David Henley, Claire Higham, EW Hoving, Charlotte Höybye, Atsuhiro Ichihara, Marie-Lise Jaffrain-Rea, Gudmundur Johannsson, Jens Otto Lunde Jorgensen, Christel Jublanc, Jan Komor, Marta Korbonits, Ivana Kralievic, Delphine Larrieu-Ciron, Helene Lasolle, Edward Laws, Marco Losa, Dominique Maiter, Claudio Marcocci, Olinda Castro Marques, Tania Longo Mazzuco, Alexander Micko, Nathalie Bourcigaux, Sebastian Neggers, John Newell-Price, Belén Perez-Berida, Leon D Ortiz, Oskar Ragnarsson, Marta Ragonese, Martin Reincke, Jean-Louis Sadoul, Akira Shimatsu, Luis V Syro, Luc Taillandier, Miklos Toth, Takeshi Usui, Zauzsanna Valkusz, Greisa Vila, Ben Whitelaw, Maria Chiara Zatelli
Publikováno v:
European Journal of Endocrinology, 178(3), 265-276
Objective To collect outcome data in a large cohort of patients with aggressive pituitary tumours (APT)/carcinomas (PC) and specifically report effects of temozolomide (TMZ) treatment. Design Electronic survey to ESE members Dec 2015–Nov 2016. Resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a10692b3e9ae15f3c128ca31542e8d7
http://hdl.handle.net/11577/3275059
http://hdl.handle.net/11577/3275059
Autor:
Oscar Arrieta, Sandra Franco, Fernando Hakim, Leonardo Rojas, Laura Bernal, Luis Carlos Mayor, Hernán Carranza, Beatriz Wills, Carlos Vargas, Enrique Jiménez Hakim, Leon D. Ortiz, Juan Armando Mejía, Carmen Balana, Carlos Ortiz, Andrés F. Cardona, Miguel Gil-Gil, Alejandro Ruiz-Patiño, Jorge Otero, Sonia Bermúdez, Zyanya Lucia Zatarain-Barrón, Nicolás Useche
Publikováno v:
Journal of Neuro-Oncology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Epilepsy is a common symptom in patients with glioblastoma (GB). 213 patients with GB from RedLANO follow-up registry were included. All patients underwent surgery, if feasible, followed by chemoradiation based on temozolomide (Stupp platform). Infor
Autor:
Gerardo Aristizabal, Juan Armando Mejía, Andrés Quintero, Germán Peña, Leon D. Ortiz, Carlos Vargas, Andrés F. Cardona, Jorge Otero, Fernando Hakim, Enrique Jiménez, Hernán Carranza, Carlos Bartels, Nicolás Useche, Sonia Bermúdez, Carlos Emilio Restrepo
Publikováno v:
Revista Colombiana de Hematología y Oncología. 2:34-44
Recently, the Neuro-oncology Working Group, Response assessment in neuro-oncology (RANO) introduced new response criteria for gliomas and its clinical implication. Establishing this working-progress platform and its first report, represent an importa
Autor:
Leon D. Ortiz, Sonia Bermúdez, Fernando Hakim, Fernando Velandia, Christian David Castro, Adriana Flórez, Carlos Andrés Quintero, Nicolás Useche, Andrés F. Cardona, Marcela Mejía, Alfredo García
Publikováno v:
Revista Colombiana de Hematología y Oncología. 1:41-47
Se presenta el caso de un hombre de 28 años con pérdida progresiva de la agudeza visual y cefalea asociada a polidipsia, poliuria e hipersomnia. La resonancia magnética cerebral mostró una masa heterogénea localizada a nivel selar/supraselar con